Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2904 | Physiology Wiki | 0.71 |
| drug695 | CETA Short Session (CSS) Wiki | 0.71 |
| drug3058 | Pravastatin Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001172 | Arthritis, Rheumatoid NIH | 0.19 |
| D001168 | Arthritis NIH | 0.16 |
| D013577 | Syndrome NIH | 0.06 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001370 | Rheumatoid arthritis HPO | 0.19 |
| HP:0001369 | Arthritis HPO | 0.16 |
Navigate: Correlations HPO
There are 2 clinical trials
Objective: To assess whether adjunctive therapy of COVID-19 infection with atorvastatin reduces the deterioration in hospitalized patients and improves clinical outcome.
Description: Proportion of patients in each arm that progress to severe or critical requiring ICU admission and/or emergency salvage therapy, or death, as described by WHO Ordinal Scale for Clinical Improvement scores 5-8 with higher being worse.
Measure: Proportion of patients that progress to severe or critical requiring ICU admission and/or emergency salvage therapy, or death Time: 30 daysDescription: Description of clinical status of patients in each arm based on WHO Ordinal Scale of Clinical Improvement on Day 7, scores 1-8 with higher being worse.
Measure: Overall score of patients in each arm on Day 7 based on WHO Ordinal Scale for Clinical Improvement Time: 7 daysDescription: Description of clinical status of patients in each arm based on WHO Ordinal Scale of Clinical Improvement on Day 30, scores 1-8 with higher being worse.
Measure: Overall score of patients in each arm on Day 30 based on WHO Ordinal Scale for Clinical Improvement Time: 30 daysDescription: Proportions of patients in each arm who are tested on Day 7 and have negative PCR
Measure: Proportions of patients in each arm who test negative for SARS-CoV-2 on Day 7 Time: 7 daysThe primary objective of this study is to evaluate the effect of filgotinib on a mixed organic anion transporting polypeptide/cytochrome P450 3A (OATP/CYP3A), OATP/ breast cancer resistance protein (BCRP), and OATP substrates using phenotypic probes.
Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports